NSPR
InspireMD, Inc.
$0.7300
0.00%
$34.2M
No data for this timeframe.
Vol
Market Cap$34.2M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders7 funds
Inst. Value$3.4M
Inst. Activity1 buys / 0 sells
Insider Activity12B / 24S
Insider Net $$81.9K
SEC Reports8
Press Releases3
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001433607·Prev Close $0.7300
Recent Activity
Jun 12, 2026
regulatory
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>MIAMI, June 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “C
May 27, 2026
Insider
Stuka Paul bought 20,000 shares
Director @ $0.8750 ($17.5K)
May 21, 2026
SEC
InspireMD insiders show mixed activity: CEO Marvin Slosman and Director Paul Stuka made open-market purchases totaling ~
CLUSTER — Impact 4/10
May 19, 2026
Insider
Gleason Shane Thomas sold 22,778 shares
Chief Commercial Officer @ $1.01 ($23.0K)
May 15, 2026
SEC
Four InspireMD insiders, including CEO Marvin Slosman and three directors, collectively purchased $227K in open-market s
CLUSTER — Impact 6/10
May 14, 2026
Insider
Stuka Paul bought 5,000 shares
Director @ $1.15 ($5.8K)
May 12, 2026
SEC
Three directors at InspireMD (NSPR) purchased a total of $267K in open-market shares over the past week, representing 0.
CLUSTER — Impact 5/10
Inst.
BlackRock, Inc. — ADD
80,449 shares ($131.1K)
Price Targets
$3.67
+402.3% upside
Strong Buy
Current $0.7300
Low $3.00
Median $4.00
High $4.00
3 analysts
$3.00
$4.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | Piper Sandler | REITERATE | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.20 ▼ -9.1% | $-0.21 — $-0.19 | 23% YoY | 3 |
| Next Q | $-0.19 ▼ -3.7% | $-0.20 — $-0.17 | -10% YoY | 3 |
| Current FY | $-0.74 ▼ -1.8% | $-0.76 — $-0.71 | 3% YoY | 3 |
| Next FY | $-0.61 ▼ -0.5% | $-0.69 — $-0.48 | 18% YoY | 3 |
Latest Reports
NEUTRAL
CLUSTER
4/10
InspireMD insiders show mixed activity: CEO Marvin Slosman and Director Paul Stuka made open-market purchases totaling ~
May 21, 2026
BULLISH
CLUSTER
6/10
Four InspireMD insiders, including CEO Marvin Slosman and three directors, collectively purchased $227K in open-market s
May 15, 2026
BEARISH
Press
7/10
InspireMD announced a voluntary U.S. recall of its CGuard Prime 135 cm delivery system due to subpar technical performan
May 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| MARSHALL WACE, LLP | $3.0M | — |
| BlackRock, Inc. | $131.1K | ADD |
| CITADEL ADVISORS LLC | $107.2K | ADD |
| MORGAN STANLEY | $64.9K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 27, 2026 | Stuka Paul | BUY | $17.5K |
| May 19, 2026 | Gleason Shane | SELL | $23.0K |
| May 14, 2026 | Stuka Paul | BUY | $5.8K |
| May 13, 2026 | Stuka Paul | BUY | $11.6K |
| May 12, 2026 | Slosman Marvin | BUY | $25.2K |
7 institutional holders with $3.4M total value (2,088,995 shares) as of 2026-Q1. Top holders: ROYAL, MARSHALL, BlackRock,. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 180 | $0.00 | 0.0% | — |
| 2 | MARSHALL WACE, LLP | 1,860,405 | $3.0M | 89.1% | — |
| 3 | BlackRock, Inc. | 80,449 | $131.1K | 3.9% | ADD +32.1% |
| 4 | CITADEL ADVISORS LLC | 65,750 | $107.2K | 3.1% | ADD +45.0% |
| 5 | MORGAN STANLEY | 39,836 | $64.9K | 1.9% | TRIM -51.4% |
| 6 | Centiva Capital, LP | 24,766 | $40.4K | 1.2% | — |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 17,609 | $28.7K | 0.8% | DOUBLED +201.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 60,895 | 80,449 | +32.1% | $131.1K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 86,011 | 41,833 | -51.4% | $74.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 608 | 113 | -81.4% | $201.00 | 2025-Q4 |
| BlackRock, Inc. | ADD | 36,573 | 53,714 | +46.9% | $129.5K | 2025-Q3 |
| CITADEL ADVISORS LLC | ADD | 26,176 | 37,954 | +45.0% | $91.5K | 2025-Q3 |
| RAYMOND JAMES FINANCIAL INC | ADD | 34,604 | 44,604 | +28.9% | $101.3K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 124,301 | 71,266 | -42.7% | $191.7K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 10,400 | 31,378 | +201.7% | $84.4K | 2025-Q1 |
| MORGAN STANLEY | ADD | 89,494 | 124,301 | +38.9% | $326.9K | 2024-Q4 |
5 unique insiders with 36 transactions. Net insider value: $81.9K ($370.8K bought, $288.9K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 27, 2026 | Stuka Paul | Director | BUY | 20,000 | $0.8750 | $17.5K |
| May 19, 2026 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 22,778 | $1.01 | $23.0K |
| May 14, 2026 | Stuka Paul | Director | BUY | 5,000 | $1.15 | $5.8K |
| May 13, 2026 | Stuka Paul | Director | BUY | 10,000 | $1.16 | $11.6K |
| May 12, 2026 | Slosman Marvin | CEO and President | BUY | 21,000 | $1.20 | $25.2K |
| May 11, 2026 | Stuka Paul | Director | BUY | 10,000 | $1.19 | $11.9K |
| May 8, 2026 | Stuka Paul | Director | BUY | 65,626 | $1.16 | $76.1K |
| May 7, 2026 | ROUBIN GARY S | Director | BUY | 90,000 | $1.18 | $106.2K |
| May 7, 2026 | Stuka Paul | Director | BUY | 6,378 | $1.15 | $7.3K |
| May 7, 2026 | Ward Scott R. | Director | BUY | 73,255 | $1.15 | $84.2K |
| May 6, 2026 | Ward Scott R. | Director | BUY | 15,995 | $1.15 | $18.4K |
| May 6, 2026 | Stuka Paul | Director | BUY | 1,517 | $1.12 | $1.7K |
| Feb 2, 2026 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 2,941 | $1.59 | $4.7K |
| Feb 2, 2026 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 2,000 | $1.60 | $3.2K |
| Jan 30, 2026 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 2,900 | $1.63 | $4.7K |
| Jan 29, 2026 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 5,000 | $1.65 | $8.3K |
| Jan 28, 2026 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 12,395 | $1.65 | $20.5K |
| Jan 27, 2026 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 4,781 | $1.66 | $8.0K |
| Jan 22, 2026 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 8,411 | $1.57 | $13.2K |
| Jan 21, 2026 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 17,593 | $1.62 | $28.6K |
| Jan 20, 2026 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 2,955 | $1.59 | $4.7K |
| Jan 16, 2026 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 2,250 | $1.61 | $3.6K |
| Jan 15, 2026 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 2,909 | $1.58 | $4.6K |
| Dec 9, 2025 | Stuka Paul | Director | BUY | 2,710 | $1.81 | $4.9K |
| May 30, 2025 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 7,186 | $2.51 | $18.0K |
| May 29, 2025 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 3,760 | $2.51 | $9.4K |
| May 27, 2025 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 1,572 | $2.51 | $3.9K |
| May 23, 2025 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 2,482 | $2.51 | $6.2K |
| Feb 25, 2025 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 10,000 | $3.65 | $36.5K |
| Feb 4, 2025 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 5,132 | $2.46 | $12.6K |
| Feb 3, 2025 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 7,073 | $2.51 | $17.8K |
| Jan 31, 2025 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 9,923 | $2.55 | $25.3K |
| Jan 30, 2025 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 2,454 | $2.51 | $6.2K |
| Jan 29, 2025 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 3,660 | $2.46 | $9.0K |
| Jan 28, 2025 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 2,476 | $2.61 | $6.5K |
| Jan 27, 2025 | Gleason Shane Thomas | Chief Commercial Officer | SELL | 3,858 | $2.71 | $10.5K |
8 SEC filing reports analyzed. Sentiment: 2 bullish, 2 bearish, 0 mixed, 4 neutral. Avg impact: 4.9/10.
NEUTRAL
CLUSTER
4/10
InspireMD insiders show mixed activity: CEO Marvin Slosman and Director Paul Stuka made open-market
May 21, 2026
BULLISH
CLUSTER
6/10
Four InspireMD insiders, including CEO Marvin Slosman and three directors, collectively purchased $2
May 15, 2026
BULLISH
CLUSTER
5/10
Three directors at InspireMD (NSPR) purchased a total of $267K in open-market shares over the past w
May 12, 2026
BEARISH
8-K
7/10
InspireMD initiated a voluntary U.S. recall of its CGuard Prime 135 cm delivery system due to perfor
May 1, 2026
NEUTRAL
DEFA14A
4/10
InspireMD, Inc. issued a supplemental proxy statement clarifying that Proposal 2 — increasing the au
Apr 22, 2026
NEUTRAL
DEFA14A
3/10
InspireMD, Inc. filed a definitive proxy statement (DEFA14A) for its annual shareholder meeting. The
Apr 20, 2026
BEARISH
424B5
6/10
InspireMD is establishing an at-the-market equity offering program to sell up to $75 million of comm
Apr 3, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K reports Items 2.0
Mar 18, 2026
BEARISH
7/10
InspireMD announced a voluntary U.S. recall of its CGuard Prime 135 cm delivery system due to subpar
May 1, 2026
BULLISH
6/10
InspireMD received FDA IDE approval for its CGUARDIANS III pivotal study of the SwitchGuard neuro pr
May 1, 2026
NEUTRAL
3/10
InspireMD announced it will release its Q4 and full-year 2025 financial results on March 18, 2026, f
Mar 9, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$3.67 mean target
+402.3% upside
Strong Buy (1.67)
$3.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $0.7300 |
| Target Low | $3.00 |
| Target Mean | $3.67 |
| Target Median | $4.00 |
| Target High | $4.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.67) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.20 | $-0.21 | $-0.19 | 23.1% | -9.1% | 0↑ 2↓ | $0.0B | -22.2% | 3 |
| Next Q 2026-09-30 |
$-0.19 | $-0.20 | $-0.17 | -9.8% | -3.7% | 0↑ 1↓ | $0.0B | -15.5% | 3 |
| Current FY 2026-12-31 |
$-0.74 | $-0.76 | $-0.71 | 2.6% | -1.8% | 0↑ 2↓ | $0.0B | 15.6% | 3 |
| Next FY 2027-12-31 |
$-0.61 | $-0.69 | $-0.48 | 17.6% | -0.5% | 1↑ 1↓ | $0.0B | 111.2% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.200 | |
| 7d ago | $-0.183 | -0.017 |
| 30d ago | $-0.183 | -0.017 |
| 60d ago | $-0.203 | +0.003 |
| 90d ago | $-0.203 | +0.003 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 12, 2026
regulatory
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>MIAMI, June 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid s
Jun 8, 2026
other
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures
<p align="justify">MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard<s
May 4, 2026
earnings
InspireMD Reports First Quarter 2026 Financial Results
<p align="center"> <em>- Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% -</em></p>
May 4, 2026
earnings_calendar
NSPR Q1 2026 Earnings Scheduled — 2026-05-04
May 1, 2026
fda
InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System
<p align="center"><em>- Strong clinical demand continues in Q1 2026 with global year-over-year unit sales growth of 53% and quarter-over-quarter U.S.
May 1, 2026
fda
InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
<p align="justify">MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard<su
Mar 31, 2026
other
InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference
<p>MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard<sup>®</sup> Prime carotid stent system for the
Mar 18, 2026
earnings_calendar
NSPR Q4 2025 Earnings After Market Close — 2026-03-18
Mar 10, 2026
earnings_calendar
NSPR Q4 2025 Earnings After Market Close — 2026-03-10
Mar 9, 2026
earnings
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
<p>MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard<sup>®</sup> Prime carotid stent system for the